Inflammatory monocytes are potent antitumor effectors controlled by regulatory CD4+T cells

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 32, 2013, Pages 13085-13090

  Pommier, Arnaud ^a,b,c   Audemard, Alexandra ^a,b,c   Durand, Aurélie ^a,b,c   Lengagne, Renée ^a,b,c   Delpoux, Arnaud ^a,b,c   Martin, Bruno ^a,b,c   Douguet, Laetitia ^a,b,c   Le Campion, Armelle ^a,b,c   Kato, Masashi ^d   Avril, Marie Françoise ^a,b,c   Auffray, Cédric ^a,b,c   Lucas, Bruno ^a,b,c   Prévost Blondel, Armelle ^a,b,c  

^a CNRS   (France)

^b INSERM   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 10;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DEPIGMENTATION; DISEASE COURSE; DISTANT METASTASIS; MELANOCYTE; MELANOMA; METASTASIS; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SKIN; SKIN METASTASIS; SPLEEN; TUMOR GROWTH; VITILIGO;

ANIMALS; CELL PROLIFERATION; FEMALE; FLOW CYTOMETRY; HUMANS; INFLAMMATION; LYMPH NODES; MALE; MELANOMA; METALLOTHIONEIN; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; MONOCYTES; NEOPLASM METASTASIS; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-RET; REACTIVE OXYGEN SPECIES; SKIN; SPLEEN; T-LYMPHOCYTES, REGULATORY; TIME FACTORS; VITILIGO;

EID: 84881416837     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1300314110     Document Type: Article

References (46)

1. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M (1995) Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 155(3):1151-1164.
2. Hori S, Nomura T, Sakaguchi S (2003) Control of regulatory T cell development by the transcription factor Foxp3. Science 299(5609):1057-1061.
3. 2+ effector T cells. J Exp Med 159(5):1295-1311.
4. +T cells: A common basis between tumor immunity and autoimmunity. J Immunol 163(10):5211-5218.
5. +T helper cells and hindered by naturally occurring T regulatory cells. J Immunol 174(5):2591-2601.
6. Chaput N, et al. (2007) Regulatory T cells prevent CD8 T cell maturation by inhibiting CD4 Th cells at tumor sites. J Immunol 179(8):4969-4978.
7. Darrasse-Jèze G, et al. (2009) Tumor emergence is sensed by self-specific CD44hi memory Tregs that create a dominant tolerogenic environment for tumors in mice. J Clin Invest 119(9):2648-2662.
8. Quezada SA, Peggs KS, Simpson TR, Allison JP (2011) Shifting the equilibrium in cancer immunoediting: From tumor tolerance to eradication. Immunol Rev 241(1):104-118.
9. Boissonnas A, et al. (2010) Foxp3+ T cells induce perforin-dependent dendritic cell death in tumor-draining lymph nodes. Immunity 32(2):266-278.
10. Fujimura T, Ring S, Umansky V, Mahnke K, Enk AH (2012) Regulatory T cells stimulate B7-H1 expression in myeloid-derived suppressor cells in ret melanomas. J Invest Dermatol 132(4):1239-1246.
11. Kato M, et al. (1998) Transgenic mouse model for skin malignant melanoma. Oncogene 17(14):1885-1888.
12. Eyles J, et al. (2010) Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma. J Clin Invest 120(6):2030-2039.
13. Toh B, et al. (2011) Mesenchymal transition and dissemination of cancer cells is driven by myeloid-derived suppressor cells infiltrating the primary tumor. PLoS Biol 9(9):e1001162.
14. + T cells. Cancer Res 64(4):1496-1501.
15. Bystryn JC, Rigel D, Friedman RJ, Kopf A (1987) Prognostic significance of hypopigmentation in malignant melanoma. Arch Dermatol 123(8):1053-1055.
16. Duhra P, Ilchyshyn A (1991) Prolonged survival in metastatic malignant melanoma associated with vitiligo. Clin Exp Dermatol 16(4):303-305.
17. Quaglino P, et al. (2010) Vitiligo is an independent favourable prognostic factor in stage III and IV metastatic melanoma patients: Results from a single-institution hospital- based observational cohort study. Ann Oncol 21(2):409-414.
18. Byrne KT, Turk MJ (2011) New perspectives on the role of vitiligo in immune responses to melanoma. Oncotarget 2(9):684-694.
19. Viguier M, et al. (2004) Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 173(2):1444-1453.
20. Jacobs JF, Nierkens S, Figdor CG, de Vries IJ, Adema GJ (2012) Regulatory T cells in melanoma: The final hurdle towards effective immunotherapy? Lancet Oncol 13(1):e32-e42.
21. Lengagne R, et al. (2011) T cells contribute to tumor progression by favoring protumoral properties of intra-tumoral myeloid cells in a mouse model for spontaneous melanoma. PLoS ONE 6(5):e20235.
22. Lengagne R, et al. (2008) Distinct role for CD8 T cells toward cutaneous tumors and visceral metastases. J Immunol 180(1):130-137.
23. Sandoval-Cruz M, et al. (2011) Immunopathogenesis of vitiligo. Autoimmun Rev 10(12):762-765.
24. Serbina NV, Pamer EG (2006) Monocyte emigration from bone marrow during bacterial infection requires signals mediated by chemokine receptor CCR2. Nat Immunol 7(3):311-317.
25. Soudja SM, et al. (2010) Tumor-initiated inflammation overrides protective adaptive immunity in an induced melanoma model in mice. Cancer Res 70(9):3515-3525.
26. Bronkhorst IH, Jager MJ (2012) Uveal melanoma: The inflammatory microenvironment. J Innate Immun 4(5-6):454-462.
27. Piras F, et al. (2005) The predictive value of CD8, CD4, CD68, and human leukocyte antigen-D-related cells in the prognosis of cutaneous malignant melanoma with vertical growth phase. Cancer 104(6):1246-1254.
28. Varney ML, Johansson SL, Singh RK (2005) Tumour-associated macrophage infiltration, neovascularization and aggressiveness in malignant melanoma: Role of monocyte chemotactic protein-1 and vascular endothelial growth factor-A. Melanoma Res 15(5):417-425.
29. Nizar S, Meyer B, Galustian C, Kumar D, Dalgleish A (2010) T regulatory cells, the evolution of targeted immunotherapy. Biochim Biophys Acta 1806(1):7-17.
30. Kimpfler S, et al. (2009) Skin melanoma development in ret transgenic mice despite the depletion of CD25+Foxp3+ regulatory T cells in lymphoid organs. J Immunol 183(10): 6330-6337.
31. Ben Ahmed M, et al. (2012) Functional defects of peripheral regulatory T lymphocytes in patients with progressive vitiligo. Pigment Cell Melanoma Res 25(1):99-109.
32. Klarquist J, et al. (2010) Reduced skin homing by functional Treg in vitiligo. Pigment Cell Melanoma Res 23(2):276-286.
33. + cytotoxic T lymphocytes correlates with an impairment in regulatory T cells in patients with generalized vitiligo. PLoS ONE 7(5):e37513.
34. Le Gal FA, et al. (2001) Direct evidence to support the role of antigen-specific CD8(+) T cells in melanoma-associated vitiligo. J Invest Dermatol 117(6):1464-1470.
35. Ogg GS, Rod Dunbar P, Romero P, Chen JL, Cerundolo V (1998) High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo. J Exp Med 188(6):1203-1208.
36. + memory T cell responses to mouse melanoma. J Clin Invest 121(5):1797-1809.
37. Auffray C, et al. (2009) CX3CR1+ CD115+ CD135+ common macrophage/DC precursors and the role of CX3CR1 in their response to inflammation. J Exp Med 206(3):595-606.
38. Auffray C, Sieweke MH, Geissmann F (2009) Blood monocytes: Development, heterogeneity, and relationship with dendritic cells. Annu Rev Immunol 27:669-692.
39. te Velde AA, Figdor CG (1992) Monocyte mediated cytotoxic activity against melanoma. Melanoma Res 1(5-6):303-309.
40. Griffith TS, et al. (1999) Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL. J Exp Med 189(8):1343-1354.
41. Martin JH, Edwards SW (1993) Changes in mechanisms of monocyte/macrophagemediated cytotoxicity during culture. Reactive oxygen intermediates are involved in monocyte-mediated cytotoxicity, whereas reactive nitrogen intermediates are employed by macrophages in tumor cell killing. J Immunol 150(8 Pt 1):3478-3486.
42. Rubtsov YP, et al. (2008) Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces. Immunity 28(4):546-558.
43. Bosschaerts T, et al. (2010) Tip-DC development during parasitic infection is regulated by IL- 10 and requires CCL2/CCR2, IFN-gamma and MyD88 signaling. PLoS Pathog 6(8):e1001045.
44. Qian BZ, et al. (2011) CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 475(7355):222-225.
45. Lesokhin AM, et al. (2012) Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment. Cancer Res 72(4):876-886.
46. Wolf MJ, et al. (2012) Endothelial CCR2 signaling induced by colon carcinoma cells enables extravasation via the JAK2-Stat5 and p38MAPK pathway. Cancer Cell 22(1):91-105.